HomeQuestion
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
2
2 Answers
Mednet Member
Medical Oncology · Mary Lanning Healthcare Morrison Cancer Center/University of Nebraska Medical Center Adjunct Faculty
The hormone receptor-positive, HER2-positive (HR+/HER2+) breast cancer subtype is a distinct clinical entity from hormone receptor-negative, HER2-positive (HR−/HER2+) breast cancer. Moreover, there is heterogeneity among HR+/HER2+ tumors. The main oncogenic driver may vary among HR+/HER2+ patients w...
Mednet Member
Medical Oncology · Warren Alpert Medical School of Brown University
As opposed to combining hormonal therapies with HER2-targeted therapies that are intended to block signaling through the HER2 pathway, such as trastuzumab or the combination of trastuzumab and pertuzumab, whether administered in place of or after a course of chemotherapy combined with those HER2-tar...